Patents by Inventor Robert D. Colucci
Robert D. Colucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170020865Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: October 7, 2016Publication date: January 26, 2017Inventors: Robert F. KAIKO, Robert D. COLUCCI
-
Patent number: 9474750Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: August 15, 2014Date of Patent: October 25, 2016Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Publication number: 20160051539Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: November 3, 2015Publication date: February 25, 2016Inventors: Robert F. KAIKO, Robert D. Colucci
-
Patent number: 9205082Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: March 14, 2014Date of Patent: December 8, 2015Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Publication number: 20150025101Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: September 18, 2014Publication date: January 22, 2015Inventors: Robert F. KAIKO, Robert D. COLUCCI
-
Patent number: 8936808Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: September 18, 2014Date of Patent: January 20, 2015Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Patent number: 8932630Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: September 18, 2014Date of Patent: January 13, 2015Assignee: Purdue Pharma L.PInventors: Robert F. Kaiko, Robert D. Colucci
-
Publication number: 20150005336Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: September 18, 2014Publication date: January 1, 2015Inventors: Robert F. KAIKO, Robert D. Colucci
-
Publication number: 20140357658Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: August 15, 2014Publication date: December 4, 2014Inventors: Robert F. KAIKO, Robert D. Colucci
-
Patent number: 8822487Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: December 7, 2012Date of Patent: September 2, 2014Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Publication number: 20140200236Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: PURDUE PHARMA L.P.Inventors: Robert F. KAIKO, Robert D. Colucci
-
Patent number: 8673355Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: December 27, 2011Date of Patent: March 18, 2014Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Publication number: 20120165359Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: December 27, 2011Publication date: June 28, 2012Applicant: PURDUE PHARMA L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Patent number: 8105631Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: May 24, 2010Date of Patent: January 31, 2012Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Patent number: 7943173Abstract: Disclosed in certain embodiments is a pharmaceutical composition comprising from 10 to 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 0.65 to 0.90 mg naloxone or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 18, 2002Date of Patent: May 17, 2011Assignee: Purdue Pharma L.P.Inventors: Christopher D. Breder, Robert D. Colucci, Stephen A Howard, Benjamin Oshlack, Curtis Wright
-
Publication number: 20100291203Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: May 24, 2010Publication date: November 18, 2010Applicant: PURDUE PHARMA L.P.Inventors: ROBERT F. KAIKO, Robert D. Colucci
-
Patent number: 7749542Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: July 28, 2008Date of Patent: July 6, 2010Assignee: Purdue Pharma LPInventors: Robert F. Kaiko, Robert D. Colucci
-
Publication number: 20080292694Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: July 28, 2008Publication date: November 27, 2008Applicant: PURDUE PHARMA L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Patent number: 7419686Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: December 26, 2006Date of Patent: September 2, 2008Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Patent number: 7172767Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: October 27, 2003Date of Patent: February 6, 2007Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci